| Project/Area Number |
63570346
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
NAGAI Akihiko Niigata University, Medical Hospital, Lecturer., 医学部・附属病院, 講師 (00164377)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
CHOU Takaaki Niigata University, Medical Hospital, Assistant., 通信部・附属病院, 助手
|
|---|
| Project Period (FY) |
1988 – 1989
|
| Project Status |
Completed (Fiscal Year 1989)
|
| Budget Amount *help |
¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 1989: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1988: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | IVS system / TIL / Adoptive immunotherapy / BAL / adoptive immunotheropy / LAK / adoptive immunotherapy |
|---|
| Research Abstract |
The purpose of this research was to induce and manipulate the immunologically specific tumor infiltrating lymphocytes(TIL) from patients with lung cancer by means of in vitro sensitization(IVS) system, utilizing human recombinant interleukin-2(rIL2), for the specific adoptive immunotherapy against lung cancer.
At first, we have demonstrated the following results using MCA 105 cell line established from mouse fibrosarcoma; (1) IVS culture adopting low dose rIL2 induced more effective antitumor immune lymphocytes, whereas high dose rIL2 use mediated lymphokine activated killer (LAK) cells with nonspecific antitumor activity, (2) although in vivo antitumor activity of IVS cells originated from spleen cells of MCA 105 immune mouse was MCA 105 specific, IVS cells obtained from MCA 105 tumor bearing mouse showed cross reactivity to MCA 106 tumor cells; which revealed that the antitumor immune response generated along with tumor growth was different from the antitumor immune response caused by active immunization utilizing such a nonspecific immunopotentiator as corynebacterium pavum.
Next, we made a clinical protocol in which induced IVS cells from the mixed peripheral lymphocytes tumor cells culture were put into the pleural and peritoneal space of patients with malignant pleural and peritoneal effusion, and we treated 6 patients with primary lung cancer, 2 patients with metastatic lung cancer according to the protocol. This treatment was effective in 3 patients with primary lung cancer.
We reported these clinical results, as well as the results of mouse experiments, in the annual meeting of the Japanese Cancer Association, the Japan Lung Cancer Society and the Japanese Society of Biological Response Modifiers in 1989.
|
